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Network-Based Multiple Sclerosis Pathway Analysis
with GWAS Data from 15,000 Cases and 30,000 Controls
International Multiple Sclerosis Genetics Consortium1,*
Multiple sclerosis (MS) is an inflammatory CNS disease with a substantial genetic component, originally mapped to only the human
leukocyte antigen (HLA) region. In the last 5 years, a total of seven genome-wide association studies and one meta-analysis successfully
identified 57 non-HLA susceptibility loci. Here, we merged nominal statistical evidence of association and physical evidence of interac-
tion to conduct a protein-interaction-network-based pathway analysis (PINBPA) on two large genetic MS studies comprising a total of
15,317 cases and 29,529 controls. The distribution of nominally significant loci at the gene level matched the patterns of extended link-
age disequilibrium in regions of interest. We found that products of genome-wide significantly associated genes are more likely to
interact physically and belong to the same or related pathways.We next searched for subnetworks (modules) of genes (and their encoded
proteins) enriched with nominally associated loci within each study and identified those modules in common between the two studies.
We demonstrate that these modules are more likely to contain genes with bona fide susceptibility variants and, in addition, identify
several high-confidence candidates (including BCL10, CD48, REL, TRAF3, and TEC). PINBPA is a powerful approach to gaining further
insights into the biology of associated genes and to prioritizing candidates for subsequent genetic studies of complex traits.Introduction
Genome-wide association studies (GWASs) are a powerful
approach to examining the genetic components of com-
plex diseases. A commonly utilized strategy in the analysis
of GWASs involves the evaluation of individual markers
with the use of a genome-wide significance cutoff p value
of 53 108 under the assumption of independence among
markers. This approach minimizes false discoveries and
has indeed enjoyed remarkable success by uncoveringmul-
tiple variants associated with complex diseases and traits.1
However, the very small fraction of both the heritable
component and the population disease burden explained
by the polymorphisms identified in most GWAS initiatives
suggest that a sizable proportion of risk alleles are still
being missed by this strategy.2,3 It is likely that alternative
GWAS-data-analysis approaches that focus on the com-
bined effects of many loci, each making a small contribu-
tion to overall disease susceptibility, might reveal insights
into the genetic basis of common chronic disease. An
interesting study by the International Schizophrenia
Consortium proved that by the analysis of markers en
masse with a significance threshold as modest as 0.1,
important information can be obtained from a well-
powered GWAS.4 More recently, a similar approach was
applied to multiple sclerosis (MS [MIM 126200]) with the
use of data from two independent GWASs and implicated
thousands of markers with p < 0.2, suggesting a clear poly-
genic model of disease susceptibility.5
Furthermore, it is highly probable that results of univar-
iate, single-locus analyses contain informative trends that,
when viewed in the contexts of genetic networks and
fundamental molecular pathways, can expose aspects of
the polygenic basis of disease susceptibility. A number of1A full list of International Multiple Sclerosis Genetics Consortium members c
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of genes and markers have been reported and have ranged
from the simple computation of overrepresentation of
associated loci in gene ontology (GO) or KEGG path-
ways6 up to more elaborated methods using enrichment of
gene sets.7–10 An advanced modification of these methods
incorporates the use of protein-interaction networks (PINs)
and searches for subnetworks (modules) enriched with
the associated genes. This approach increases the prior
probability of an association by merging statistical evi-
dence of marker-gene association and physical evidence
of interaction among those gene products (proteins).
Several versions of this approach have been reported in
multiple complex traits, including autoimmune and
neurological diseases.11–18
MS is a common inflammatory CNS disease with a well-
documented genetic component.19,20 Seven moderately
powered but independent GWASs and one meta-analysis
were reported between 2007 and 2011 and all together
identified 23 associated loci outside of the human leuko-
cyte antigen (HLA) genomic region.21–27 Later, a meta-
analysis (referred to as meta2.5 in this study) including
most of these samples was carried out, and evidence of as-
sociation for two additional loci was reported.28 In collab-
oration with theWellcome Trust Case Control Consortium
2 (WTCCC2), the International MS Genetics Consortium
(IMSGC) recently completed the largest MS GWAS
(referred to as the WTCCC2 data set in this study) to date
and raised the number of non-HLA genetic loci associated
with this disease to 57.29
Despite this notable progress, our understanding of MS
genetics remains incomplete. To further unravel the
missing heritability in MS, we conducted a PIN-based
pathway analysis (PINBPA) of these two largelyan be found at the end of the article
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independent GWAS MS data sets (meta2.5 and WTCCC2),
which together contained a total of more than 15,000
cases and almost 30,000 controls. We found that proteins
encoded by genes harboring risk variants are more likely
to interact and take part in the same or related pathways.
Furthermore, additional susceptibility variants were identi-
fied through this approach.Subjects and Methods
Data Sets and Preprocessing
p values for all tested SNPs (summary-level data) were collected for
two MS data sets (WTCCC2 and meta2.5) and, as controls, one
data set each for type 1 diabetes (T1D [MIM 222100]), rheumatoid
arthritis (RA [MIM 180300]), Crohn disease (CD [MIM 266600]),
coronary artery disease (CAD [MIM 611139]), hypertension (HT
[MIM 145500]), and type 2 diabetes (T2D [MIM 125853]) (all
from WTCCC1).30 All data sets are composed of samples of Euro-
pean descent. The WTCCC2 MS data set29 consists of 9,772 cases
and 17,376 controls analyzed with the Illumina Human 660-Quad
and Illumina 1.2M platforms. The meta2.5 data set is an imputa-
tion-based meta-analysis with 2,529,394 unique SNPs28 and
includes all previously published MS GWASs (5,545 cases and
12,153 controls in total) and minimum case overlap (less than
10%) with the WTCCC2 data set. Thus, these two data sets are
considered independent in the context of the present study. Table
S1, available online, summarizes details of each study used in this
work. In order to enrich for potentially functional variants, we
filtered each data set so as to keep only those SNPs that were
nonsynonymous and potentially deleterious (classified as either
probably or possibly damaging by PolyPhen-231) or located in 50
or 30 UTRs, transcription-factor binding sites (TFBSs), or histone
binding sites. To further reduce the number of redundant SNPs,
we eliminated those that were in close linkage disequilibrium
(LD) (R2 > 0.9).
All data used in this manuscript were obtained according to
procedures in agreement with the ethical standards of the respon-
sible committees on human experimentation (institutional and
national), and proper informed consent was obtained.Computing Gene-Wise p Values and Association
Blocks
Because this study examines the functional relationships of genes
and proteins, we needed to consider gene-level significance. To
that end, we used VEGAS, a previously described method of con-
verting individual SNPs into gene-wise p values.32 VEGAS assigns
SNPs to each of 17,787 autosomal genes according to positions on
the UCSC Genome Browser (hg18 assembly). For the capture of
regulatory regions and SNPs in LD, gene boundaries are defined
as 50 kb beyond the 50 and 30 UTRs of each gene. VEGAS takes
into account LD patterns between markers within a gene by using
Monte-Carlo simulations from the multivariate normal distribu-
tion on the basis of the LD structure of a set of reference individ-
uals (the HapMap2 CEU [Utah residents with ancestry from
northern and western Europe from the CEPH collection] popula-
tion). In VEGAS, the number of simulations per gene is deter-
mined adaptively. In the first stage, 103 simulations are performed.
If the resulting empirical p value is less than 0.1, 104 simulations
are then performed. If the empirical p value from 104 simulations
is less than 0.001, the program will perform 106 simulations. AtThe Ameach stage, the simulations are mutually exclusive. For computa-
tional reasons, if the empirical p value is 0, then no more simula-
tions will be performed. An empirical p value of 0 from 106
simulations can be interpreted as p < 106, which exceeds a
Bonferroni-corrected threshold of p < 2.8 3 106 (z0.05/
17,787; this threshold is likely to be conservative given the overlap
between genes).
We defined association blocks as those groups of sequential
genes with a p value < 0.05. A block_id was assigned to each asso-
ciation block along the genome for each study.PINBPA
We downloaded the entire iRefIndex database, a collection of 15
human PIN data sets from different sources, and computed the
union data set. This set comprised more than 400,000 interac-
tions among ~25,000 proteins. However, many of these interac-
tions were either predicted or backed up by a single experiment
(i.e., a single publication). In order to minimize the rate of false
positives, we then filtered this large network to keep only those
interactions that were described in at least two independent
publications. This resulted in a network of 8,960 proteins (nodes)
and 27,724 interactions (edges). We used this high-confidence
network for all subsequent analyses. The network was uploaded
into Cytoscape 2.8.2 and annotated with genomic position,
gene-wise p value, block_id, and bona fide genes (loaded as
node attributes) for all studies analyzed. To avoid the complexity
of the HLA region, we did not include p values for genes mapping
to the 6p21.3 region as attributes. However, the nodes corre-
sponding to those genes were left in the network, given that
they might still participate in relevant subnetworks with other
significant genes.
For each data set, we computed significant first-order interac-
tions by filtering the main network so as to keep only those genes
(and their encoded proteins) with VEGAS p values < 0.05. Then,
the number of resulting nodes and edges and the size of the largest
connected component were computed within Cytoscape. To eval-
uate the likelihood that these numbers were obtained by chance
(as a consequence of the sheer number of interactions), we
computed 1,000 simulations by assigning p values at random
from the same network and creating subnetworks of similar size.
These simulations were used as background for estimating the
significance of the subnetworks obtained with the real gene-wise
p values.
We then used the program (plugin) jActiveModules to con-
duct searches of subnetworks enriched with (but not neces-
sarily composed of) genes with significant p values. Although
jActiveModules was originally designed to discover ‘‘active’’ sub-
networks by evaluating network connectedness among differen-
tially expressed transcripts, we adapted it to take association
p values instead.33 jActiveModules starts by converting each
gene p value into a Z score by using the inverse normal cumulative
distribution function. Then, it produces an aggregate Z score (ZA)
for an entire subnetwork A of k genes by summing the Zi over all
genes in the subnetwork ZA ¼ 1=
ffiffiffi
k
p P
i˛AZi.
For the proper capture of the connection between genetic asso-
ciation and network topology, the probability of obtaining a given
ZA score by chancemust be evaluated. This is accomplished by the
random sampling of gene sets of size k with a Monte Carlo
approach, computing their ZA scores, and then using these for
deriving estimates for the score mean mk and SD sk for each k.
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of k, noise in the Monte Carlo estimates could be reduced with the
use of a sliding-window average. Thus, the corrected subnetwork
score SA is SA ¼ ðZA  mkÞ=sk. We took an SA > 3 as evidence of a
biologically active subnetwork.
GO and Cell-Specific Expression of Candidate Genes
The reported biological significance of gene sets was evaluated by
GO analysis (biological process FAT set) with the use of DAVID34
with the following parameters: similarity term overlap ¼ 10, sim-
ilarity threshold¼ 0.50, initial groupmembership¼ 5, final group
membership ¼ 3, multiple linkage threshold ¼ 0.50, and EASE ¼
0.01. For pathways, we used the KEGG set and default parameters.
Cell-specific expression was assessed with the Gene Enrichment
Profiler (see Web Resources).35 This tool computes the expression
and enrichment of any set of query genes on the basis of a refer-
ence set obtained from 126 normal tissues and cell types (repre-
sented by 557 microarrays).
Additional analysis and plots were performed with the R statis-
tical package.
Domain Knowledge Score
To prioritize unreported associations, we used a custom tool
named domain knowledge score (DKS). DKS was programmed in
R and works by performing sequential automated PubMed
searches with each gene from a custom list and any combination
of search terms. In this article, we combined each gene symbol of
interest with the terms ‘‘multiple sclerosis,’’ ‘‘inflammation,’’ or
‘‘immunity.’’ In order to also capture older articles that might refer
to outdated gene identifications, the tool also searches for all
synonyms and aliases within a specific species. The score that
each gene gets is simply the number of PubMed articles (excluding
reviews) retrieved with the input search terms. The DKS tool is
available upon request.Results
Here, we describe amultianalytical approach to integrating
two large genomic data sets inMS (Figure S1). Through this
approach, we merge statistical evidence of association and
physical evidence of interaction at the protein level to
identify associated loci and highlight functional pathways
involved in disease susceptibility.
Nominal Gene-Level Associations Cluster into Blocks
We utilized individual SNP-wise summary-level data from
two largely independent GWASs in MS to compute gene-
level p values with VEGAS.32 The first of these two studies
comprised 9,772 cases and 17,376 controls and was
recently published by the IMSGC and the WTCCC2.29
The second study was a meta-analysis encompassing all
previous GWASs in MS and included a total of 5,545 cases
and 12,153 controls.28 In order to maximize the chance
that variants had a functional impact on the encoded pro-
tein, we selected the subset of 137,457 SNPs that were non-
synonymous and potentially deleterious (classified as
either probably or possibly damaging by PolyPhen-2) or
located in 50 or 30 UTRs, TFBSs, or histone binding sites.
VEGAS computes gene-wise p values by taking into
account relative genomic position, number of SNPs within856 The American Journal of Human Genetics 92, 854–865, June 6, 2a gene, and LD patterns for the appropriate ethnic back-
ground. It uses an adaptive simulation strategy to calculate
an empirical gene-based p value for each annotated gene
and defines p < 2.8 3 106 as Bonferroni significant.
Because our main hypothesis states that even modestly
associated genes might participate in biologically plausible
pathways, we considered all genes with a VEGAS-deter-
mined p < 0.05. A Manhattan-plot visualization of both
data sets at the gene level denotes the presence of associa-
tion peaks, similar to those observed with SNP-level data
(Figure 1). The distribution of nominally significant loci
at the gene level largely replicated between the studies
(see an example in the gray box in Figure 1) and closely
matched the extended-LD patterns previously observed
in regions of interest. Specifically, 665 association blocks
containing 1,997 genes were identified for the WTCCC2
data set, and 612 blocks containing 1,707 genes were
identified for the meta2.5 data set. Of these, 625 genes
overlapped, representing a much higher-than-expected
proportion (4.8-fold enrichment) compared to what would
be expected by chance (c2 test, p < 2.2 1016). Notably,
association blocks defined in this way—as a fixed genetic
distance (0.25 cM) from the lead SNP and from there to
the closest recombination hotspot from HapMap2—
closely match the boundaries of the association regions
for the 57 MS susceptibility loci recently reported by the
IMSGC.29 The overlap between studies was still significant
after exclusion of genes from the major histocompatibility
complex and from blocks implicated by the 57 WTCCC2
loci and the two additional meta2.5 associated SNPs. In
this filtered set, we found nominal association in 557
blocks (1,471 genes) from the WTCCC2 data set and in
530 blocks (1,298 genes) from meta2.5 (3.2-fold enrich-
ment, Fisher’s exact p < 2.2 1016); there was an overlap
of 271 genes.
PINBPA
We next sought to identify additional MS susceptibility
loci by combining statistical evidence of gene association
and physical evidence of interaction of their respective
gene products by using a curated human PIN data set con-
sisting of 8,960 proteins (nodes) and 27,724 interactions
(edges) (see Subjects and Methods). All subsequent experi-
ments were performed with Cytoscape, an open-source
and extensible tool for network visualization and anal-
ysis.36 When we extracted the nodes with p values < 0.05,
subnetworks of 838 nodes (401 edges) and 761 nodes
(304 edges) were generated for the WTCCC2 and
meta2.5 data sets, respectively (we refer to these as first-or-
der networks). Given that neighboring genes have been
shown to be functionally related and thus more likely to
interact,18,37 we repeated this experiment while ensuring
that only one gene per block was extracted from the
main network. This resulted in first-order networks of
462 nodes (183 edges) for the WTCCC2 data set and 414
nodes (147 edges) for the meta2.5 data set. Both subnet-
works were more connected than would be expected by013
Figure 1. Double Manhattan Plot
A Manhattan plot showing the gene-level p values of both GWASs used in this study. Gene-level p values from the WTCCC2 GWAS are
displayed at the top, and those corresponding to the meta2.5 GWAS are at the bottom. Detailed block structure is shown in an enlarged
region in chromosome 1. Blocks were defined as groups of contiguous genes with a p value% 0.05 (grayed area). The individual p value
of each gene is displayed as a colored circle ranging from green (not significant) to yellow to red (most significant). The two plots are
largely specular, denoting overall replication (see main text).chance, as demonstrated by a simulation experiment in
which 1,000 networks of similar size were extracted from
the same PIN at random (Figure 2). Of the other data sets
used as controls, T1D, CD, and RA also produced highly
connected subnetworks (Figure 2A). In each case, subnet-
works were composed of a large connected component
and several smaller networks or isolated nodes (single-
tons). When first-order networks were computed with
the use of more significant p value thresholds, most dis-
eases showed more connections than expected
(Figure S2). We also tested whether the size of the main
component was higher than what would be expected by
chance (given the number of edges in the first-order
network) and observed that less than 1% of random net-
works resulted in connected components larger than those
obtained for the WTCCC2, meta2.5, and CD data sets.
Approximately 10% of random networks resulted in con-
nected components of the size of those generated by HT
and RA (Figure 2B). Again, when first-order networksThe Amwere computed with the use of more significant p value
thresholds, most diseases showed larger connected compo-
nents than expected (Figure S3). The higher-than-expected
first-order interactions and size of the main connected
component of these networks suggest a biologically plau-
sible mechanism by which these gene sets coordinately
affect cellular behavior.
Given the small-world topology of the human protein
interactome, it is possible that a few highly connected
nodes (hubs) bring together several associated genes,
even though the hubs themselves are not associated,
thus defining biologically associated modules. To explore
this possibility, we conducted searches for subnetworks en-
riched with significant genes by using jActiveModules, a
Cytoscape plugin based on a greedy heuristic algorithm
with internal cross-validation.33 Fifteen significant and
minimally overlapping modules of sizes 5–200 were iden-
tified for the WTCCC2 data set. Similarly, 16 significant
and minimally overlapping modules of sizes 5–189 wereerican Journal of Human Genetics 92, 854–865, June 6, 2013 857
Figure 2. Connectedness of First-Order
Interaction Networks
The number of connections among signif-
icant genes was evaluated in the back-
ground of 1,000 random simulations (see
main text).
(A) The total number of edges was plotted
as a function of the number of significant
genes for each study.
(B) The size of the largest connected
component is plotted as a function of
the total number of edges. The colored
lines represent the 50th (green), 90th
(yellow), 95th (orange), and 99th (red) per-
centiles obtained through simulations
with random gene sets of similar size.identified for the meta2.5 data set (Table 1). We next
computed the union of all modules within each data set,
resulting in a single connected network of 464 nodes and
820 edges for the WTCCC2 data set and another of 605
nodes and 1,031 edges for the meta2.5 data set. Finally,
we computed the intersection of these two networks,
which yielded 118 nodes and 95 edges. Of these, 88 genes
were arranged in 13 networks of sizes 2–27, whereas the re-
maining 30 genes remained as singletons (Figure 3). We
concentrated on the 88 genes arranged in networks
because these genes and the connections among them
were independently identified in both MS studies, and as
such, we hypothesized that these would have higher
potential to include bona fide susceptibility loci. Of these
88 genes, 54 had nominally significant p values in both
WTCCC2 andmeta2.5 studies (v-shapednodes in Figure 3),
whereas the remaining 34 had significant p values in only
one or neither study. These 54 genes are of highest impor-
tance to our approach because they had significant
p values in both studies and because they were identified
as components of significant networks in both studies as
well. Notably, 30 of these genes either contain bona fide
susceptibility variants (n ¼ 13) or are located within
bona fide associated regions (n¼ 17) (Table 1 and Figure 4),
thus representing a specificity of 56% (Table S2 lists all
blocks harboring genes with bona fide susceptibility vari-
ants and allows comparison of block structure between
the WTCCC2 and meta2.5 data sets). Considering that
only 34 of the 57 MS susceptibility loci identified to date
are represented in the PIN, this approach was able to iden-
tify bona fide MS susceptibility loci with a sensitivity of
88%. Although an independent replication is warranted
for firmly establishing whether the remaining 24 genes
are indeed associated, the high recall observed with the
network-based approach lends support to their involve-
ment inMS susceptibility (Table S3 lists the complete block
structure of each of these candidates in the WTCCC2 and
meta2.5 studies).
When we explored the 30 singleton genes in the inter-
section network, we found that 26 of them had nominally
significant p values in both studies (Table 2, bold entries).
Although these genes ended up as singletons in the inter-
section network, each of them was part of a connected858 The American Journal of Human Genetics 92, 854–865, June 6, 2network in either the WTCCC2 or the meta2.5 individual
study. Therefore, we also evaluated to what extent these
genes (significant in both studies but participating in net-
works in only one of them) include bona fide MS suscepti-
bility loci. Of these 26 genes, 12 either contain bona fide
susceptibility variants (n ¼ 3) or are located within bona
fide associated regions (n ¼ 9), representing a specificity
of 46% and a sensitivity of 35% (Table 1 and Figure 4).
As a control, we also evaluated the recall potential of the
154 genes that had nominally significant p values in both
studies but that were not found in networks. Only 13 of
them (8%) were bona fide MS-associated genes, and 26
(17%) were located within bona fide MS blocks. The
remaining 115 (75%) remained potential (nonvalidated)
associations (Figure 4). These findings represent a sensi-
tivity of 68% and a specificity of 25%.
All together, these results suggest that even nominally
significant genes, if replicated in more than one study,
represent a select list of candidates for further analysis.
However, in the absence of any additional evidence, the
chances of discovering genuine associations among these
genes are still hampered by a significant proportion of false
positives. These probabilities are significantly increased
when one considers those genes that, in addition to
showing (nominally) significant associations, participate
in interaction networks in at least one study. The best re-
sults, nonetheless, were obtained when nominally signifi-
cant genes were also identified as part of the same interac-
tion network in both studies.
The analysis of other WTCCC1 diseases used as
controls also supports this interpretation. In those data
sets, the average sensitivitywas 42.3%and the average spec-
ificity was 8.3%. Notably, CD yielded a sensitivity of 88%
(the same obtained for MS), albeit with a much more
modest specificity of 16% (compared with 56% for MS).
The main factors contributing to the significantly better
performance of the MS data sets were most likely their size
and the availability of a replication data set.
Biological Significance of Associated and Candidate
Genes in MS
To explore the biological significance of the genes with
either confirmed or suspected roles in MS susceptibility013
Table 1. Gene-Level Significance, Power, and Network Characteristics of Each GWAS
Disease MIM
Number of
Nominally
Significant Genes
Area under
ROC Curve
Size of First-Order
Interaction Net
(Nodes–Edges)
Number of
Subnetworks
(Min–Max Size)
Size of Union Net
(Nodes–Edges)
Sensitivity
(%)
Specificity
(%)
MS (WTCCC2) 126200 1,996 0.95 838–401 15 (6–200) 464–820 88 56
MS (meta2.5) 126200 1,706 0.88 761–304 16 (5–189) 605–1,031 - -
T1D 222100 1,056 0.65 474–161 13 (5–170) 378–669 30 4.4
T2D 125853 913 0.71 405–74 8 (10–211) 332–562 34 17.0
RA 180300 937 0.66 360–68 16 (6–207) 347–632 12 1.7
CD 266600 997 0.72 469–116 15 (5–231) 449–1,066 88 16.0
CAD 607339 831 0.60 393–75 15 (6–183) 299–491 52 8.3
HT 145500 813 0.64 349–40 13 (6–167) 355–500 38 2.6
Abbreviations are as follows: ROC, receiver operating characteristic; Min, minimum; Max, maximum; MS, multiple sclerosis; T1D, type 1 diabetes; T2D, type 2
diabetes; RA, rheumatoid arthritis; CD, Crohn disease; CAD, coronary artery disease; and HT, hypertension.(described in Table 2), we conducted a GO and pathway
analysis by using DAVID. Among the 79 genes in these
lists, GO analysis (biological process) identified three
main categories as significantly enriched: leukocyte activa-
tion (enrichment score ¼ 9; lead category false-discovery
rate [FDR]-corrected p value ¼ 1.3 3 108), apoptosis
(enrichment score ¼ 6.16; lead category FDR-corrected
p value ¼ 2.2 3 106), and positive regulation of macro-
molecule metabolic process (enrichment score ¼ 5.86;
lead category FDR-corrected p value ¼ 4.7 3 108). When
KEGG pathways were evaluated, the JAK-STAT signaling
pathway (enrichment score ¼ 3.47; lead category FDR-
corrected p value ¼ 1.4 3 105), acute myeloid leukemia
(enrichment score ¼ 2.22; lead category FDR-corrected
p value¼ 5.93 103), and Tcell receptor signaling (enrich-
ment score ¼ 1.63; lead category FDR-corrected p value ¼
0.01) were significantly enriched.
We also computed the tissue specificity of these genes by
using the Gene Enrichment Profiler (see Subjects and
Methods). Approximately two-thirds of these genes were
highly expressed in immune-related cell types, and about
half were highly expressed in the CNS (Figure S4, red or
black color). However, enrichment maps overwhelmingly
highlighted immune-related cell types (Figure S5). Given
that only three genes (PDE4A [MIM 600126], RAB3A
[MIM 179490], and VAMP1 [MIM 185880]) appeared to
be specifically enriched in the CNS, we were unable to
confirm our earlier observation that neural pathways
were involved in MS susceptibility.12
Finally, we used a combination of gene-level statistical
significance and text mining (DKS, see Subjects and
Methods) to highlight some of the candidate associations
emerging from the analysis (Table 2). On the basis of
stringent criteria (p < 0.01 in both studies and DKS >
50), five genes were identified as the most plausible candi-
dates: B cell lymphoma 10 (BCL10 [MIM 603517]) (DKS ¼
62), CD48 [MIM 109530] (also known as B cell mem-
brane protein) (DKS ¼ 83), v-rel reticuloendotheliosis viral
oncogene homolog (REL [MIM 164910]) (DKS ¼ 630),The AmTNF-receptor-associated factor 3 (TRAF3 [MIM 601896])
(DKS ¼ 60), and TEC protein tyrosine kinase (TEC
[MIM 600583]) (DKS ¼ 230). Although it is not possible
to unequivocally implicate any of these candidates
in MS susceptibility, in the absence of experimental
functional data, the combined strategy described here
provides a more comprehensive interpretation of these
associations.Discussion
One plausible cause of the manifestation of complex dis-
eases is the genetic alteration in the function of specific
biological pathways through the presence of multiple var-
iants in different genes (each of which contributes a
modest amount to disease predisposition) and the ultimate
disruptions in normal biological processes. We found that
even nominally associated genes (i.e., gene-level data) were
not scattered randomly across the genome but were rather
agglomerated into clusters or blocks of association in a
similar fashion to that seen in regional association plots
of SNP-level data. In fact, the gene-wise association blocks
defined in this study and the critical regions defined in the
original WTCCC2 publication are remarkably similar (see
Table S2). It is noteworthy that any other gene-wise p value
threshold would have resulted in a different arrangement
of genes into blocks, most likely smaller and fewer. Thus,
the close agreement in association-block structure and
size supports our choice of the nominal p value as a
threshold for the remainder of the study. Furthermore,
this finding has important implications, given that it indi-
cates that our strategy of selecting potentially functional
SNPs and nominally significant genes produces compara-
ble results to the more established approach utilized in
our previous study of extending a fixed genetic distance
from the lead SNP and from there to the next recombina-
tion hotspot.29 This also suggests that in most regions,
the patterns of extended LD would determine the uppererican Journal of Human Genetics 92, 854–865, June 6, 2013 859
Figure 3. Intersection Network
Of the 118 nodes obtained by the intersection of the resulting networks from each independent study, 88 were arranged in 13 subnet-
works (ranging in size from 2 to 27) and 30 nodes remained isolated. Each node represents a gene product, and each edge represents an
experimental physical interaction reported in at least two independent publications. Thus, an edge is only displayed if the same inter-
actions were identified in both studies. Isolated nodes in this representationmight still have had interactions within each of the studies,
but they were not preserved in both. White nodes are not significant. A color scale (yellow to red) denotes the significance of each node
in the WTCCC2 study. V-shaped nodes have nominally significant p values in both studies. Nodes with a yellow outline denote genes
containing bona fideMS susceptibility variants. Each of the six subnetworks with sizeR 3 is highlighted by a different background color
(subnetworks of size ¼ 2 were grouped under the same background).limit of resolution of this approach, except in cases in
which a variant with obvious functional consequence is
identified within these regions.
We have demonstrated that proteins encoded by truly
associated genes are more likely to be connected in the
PIN. By extension, we hypothesized that significant sub-
networks (enriched with nominally significant genes)
would contain genes that are more likely to be genuinely
associated. Assuming that 107 common single-nucleotide
variants exist in the human genome and that 100
of them are truly associated with MS, the prior probability
of finding an association by chance is 100,000 to 1 (105).
Theoretical calculations have suggested that the statistical-
significance cutoff required to yield an association that is
more likely true than false is directly related to its sample
size (power).38 For example, under these assumptions, a
p value of 106 is predicted to identify an association
that is ten times more likely to be true than false for a study
of 10,000 cases and 10,000 controls but equally likely to be
true or false if the size of the study is 2,000 cases and 2,000
controls. For a study with 1,000 cases and 1,000 controls,
that same p value threshold will identify associations860 The American Journal of Human Genetics 92, 854–865, June 6, 2that are ten times more likely to be false than true. These
theoretical estimates have also shown that if the prior
probability of an association is increased, for example, by
two orders of magnitude (from 105 to 103), the p value
threshold generating the same level of confidence in a
result can be reduced by roughly the same magnitude
(from 106 to 104). It follows that increasing the prior
probability is a meaningful way to increase the power of
detecting bona fide associations in a study of a given size.
Several ways to increase the prior probability of an associ-
ation exist. In this study, we aimed at increasing the prior
odds by using a three-way strategy. First, we conducted our
analysis by only using functional or potentially functional
SNPs. Because nonsynonymous coding variants and vari-
ants in regulatory regions or splice sites are more likely to
have a functional effect than are variants in silent noncod-
ing regions, concentrating analysis on these more func-
tional relevant variants is a reasonable strategy to improve
the prior odds.39 Second, we computed gene-wise p values,
thus significantly reducing the number of possible tests by
~8-fold (from 137,457 to 17,787). Third, we prioritized
candidates that were arranged in interaction networks,013
Figure 4. Proportion of Validated Dis-
coveries with a Network versus a Nonnet-
work Approach
Of the 118 genes in the intersection
network, 88 genes were arranged in 13 sub-
networks of sizes 2–27. Of those, 54 genes
were nominally significant in both studies.
Fifty-five percent of these genes either
were bona fide MS-associated genes (24%)
or fell into bona fide MS blocks (31%). Of
the 30 singletons from the 118-gene
intersection network, 26 had significant
p values in both studies. Forty-six percent
of these either were bona fide MS-associ-
ated genes (11%) or fell into bona fide
MS blocks (35%). From the 154 genes
with significant p values but not found in
networks, only 25% either were bona fide
MS-associated genes (8%) or fell into
bona fide MS blocks (17%).which as shown above, increases the likelihood of finding
true associations.
Altogether, this strategy (similar in concept to the
genomic convergence paradigm previously described40) is
likely to increase the priors, although it is not possible to
determine exactly by whichmagnitude. The fact that recall
power of the two MS data sets was large (area under the
curve of 0.95 and 0.88) further encouraged us to evaluate
genes with even modest statistical evidence of
association. Therefore, we took a liberal approach and
considered every gene-level association with a nominal
p value of 0.05. In support of this strategy, we found that
the overlap of nominally significant genes between the
WTCCC2 (n ¼ 1,997) and meta2.5 (n ¼ 1,707) studies
was 625, a 6-fold increase of what would be expected by
chance (Fisher’s exact p value < 1016).
An important finding of this study is that proteins en-
coded by nominally associated genes are more connected
in the PIN than what would be expected by chance. This
provides further evidence that in well-powered studies,
the three-way strategy followed here (selecting potentially
functional SNPs, analyzing nominal gene-level signifi-
cance, and studying genes in the context of biological
networks) maximizes the potential of finding bona fide
associations. Furthermore, this approach might highlight
the importance of a different gene than the one originally
selected within a GWAS associated block. For example, a
nonsynonymous SNP (rs3748816) in membrane metal-
loendopeptidase-like 1 (MMEL1) was originally identified
as a susceptibility gene though a screen of candidate genes
showing a p value of 3.54 3 106 (odds ratio ¼ 1.16) in
3,444 affected indviduals and 2,595 controls.41 This associ-
ation was further replicated by the WTCCC2 GWAS with a
p value of 2.25 3 1013. Its p value in meta2.5 was 2.81 3
105. However, given the extensive LD in this region, it isThe American Journal of Humanot possible to exclude the possibility
that other genes within this block are
instead associated with MS. In addi-tion to MMEL1, genes in this association block include
PLCH2 (MIM 612836), PANK4 (MIM 606162), HES5
(MIM 607348), TNFRSF14 (MIM 602746), and C1orf93.
In the present study, this region was also identified with
a block p value of 107 (genome-wide significant) in the
WTCCC2 data set and 1.49 3 104 in the meta2.5 data
set (Table S2). However, the only protein encoded by a
gene that appeared in the final intersection network in
this block was TNFRSF14, which had direct interactions
with TRAF2 (not significant) and TRAF3 (p values of
1.3 3 103 and 1.13 3 103 in the WTCCC2 and
meta2.5 data sets, respectively) (Figure 4). Furthermore,
TNFRSF14 is a ligand of TNFSF14, encoded by one of
the 57 susceptibility loci identified by the WTCCC2
GWAS. Interestingly, although physically within MMEL1,
rs3748816 was mapped to TNFRSF14 by VEGAS in the
WTCCC2 study and to both genes in the meta2.5 study,
most likely as a result of its high LD. All together, and in
the absence of additional functional experimental data,
these results provide more evidence to implicate variants
in TNFRSF14 than to implicate MMEL1 as an MS suscepti-
bility locus. Ultimately, however, experimental evidence
will be needed for determining this with precision.
Another example is the association block containing
VCAM1 (MIM 192225), EXTL2 (MIM 602411), SLC30A7
(MIM 611149), DPH5 (MIM 611075), and S1PR1 (sphingo-
sine-1-phosphate receptor 1 [MIM 601974]). Although
VCAM1 has been selected as the most likely associated
gene from this block (presumably because of its function
in cell adhesion), the WTCCC2 regional association plot
shows that this gene falls slightly outside the block, and
the most significant functional SNP maps to SLC30A7. In
this study, however, the block extends to include VCAM1
and S1PR1. Furthermore, the only gene that is significant
in both the WTCCC2 and the meta2.5 studies and showsn Genetics 92, 854–865, June 6, 2013 861
Table 2. Nominally Significant Genes in the WTCCC2 and meta2.5 Studies
Bona Fide MS Susceptibility Loci Candidate Loci
Gene Block
Gene Symbol
p Value
(WTCCC2)
p Value
(meta2.5)Gene Symbol
p Value
(WTCCC2)
p Value
(meta2.5) Gene Symbol
p Value
(WTCCC2)
p Value
(meta2.5)
CD58 2 3 105 1 3 106 TNFRSF14 1 3 107 0.00055 PHGDH 0.0008 0.00012
MERTK 0.0026 0.01698 S1PR1a 0.0261 0.00992 ETS1 0.0122 0.02008
IL12A 3 3 105 0.00066 GOLGB1 1 3 107 0.00197 TRAF3 0.0013 0.00113
IL7R 0.0005 0.00137 KIF5A 0.0002 0.00337 BCL10 2 3 105 0.00054
IL12B 4 3 106 1 3 107 CIITA 1 3 107 0.0129 CD48 9 3 106 0.00902
IL7 3 3 105 0.00339 SOCS1 1 3 107 2 3 106 REL 0.0003 0.00047
IL2RA 0.0015 0.00063 RBM17 1 3 105 0.00271 C17orf57 0.0117 0.00259
TNFRSF1A 1 3 107 0.00019 SCNN1A 2 3 106 0.00017 KPNB1 0.0002 1 3 107
STAT3 0.0001 0.00004 LTBR 2 3 106 0.00061 CHERP 0.0018 1.6 3 105
MALT1 0.0002 0.00068 CD27 0.0003 0.0125 TEC 0.0007 0.00048
CD40 0.0002 0.02198 VAMP1 0.0003 0.01662 CSF2 0.0112 0.00755
MAPK1 5 3 105 0.00063 STAT5A 0.0002 1.8 3 105 IRF1 0.0036 0.01076
SCO2 1 3 105 0.00315 STAT5B 0.0349 0.00099 EIF3B 5 3 105 0.03787
VCAM1 0.0008 0.00917 CLTC 0.0066 0.00088 JAK2 0.01 0.01543
RGS1 5 3 106 0.00076 KEAP1b 0.0019 0.03798 PAX5 0.0232 0.04573
TNFSF14 0.0002 0.00452 PFDN4 0.0001 0.01813 RIC8A 0.0061 0.02786
- - - TOP3B 0.0006 0.00695 NR1H3 0.0007 0.00472
- - - BCL2L11 0.0005 0.00101 SART1 0.0001 0.00115
- - - HCLS1 0.0035 0.0157 VPS33A 0.0091 0.00124
- - - CDK4 1 3 106 1.1 3 105 MARK3 0.0066 9.6 3 105
- - - PITPNM2 0.0002 0.00133 FBF1 0.0232 0.00657
- - - OGFOD2 0.0006 0.0032 PIK3R2 1 3 107 0.01093
- - - C3 0.0003 0.02719 PITPNB 0.0059 0.01738
- - - PDE4A 1 3 107 0.0048 BBC3 0.0006 0.01007
- - - RTEL1 4 3 105 0.00665 SLAMF1 0.008 0.0497
- - - PPM1F 0.0006 0.00458 MORF4L1 0.0105 0.0022
- - - - - - MED26 0.001 0.0002
- - - - - - TXK 0.0002 0.00039
- - - - - - IKZF1 0.0068 0.04215
- - - - - - BMI1 0.01 0.0102
- - - - - - PSMD13 0.0054 0.02084
- - - - - - FOSL1 0.007 0.02244
- - - - - - CLIP1 0.005 4.6 3 105
- - - - - - ITGAX 0.0025 0.01925
- - - - - - JUP 0.0306 0.01387
- - - - - - DNAJC7 0.0069 0.01956
- - - - - - RAB3A 1 3 105 0.01381
All genes were arranged in networks in at least one of the two studies. Genes in bold are those with significant p values in both studies but arranged as singletons in
the intersection network from Figure 3.
aThis gene is significant but falls in a contiguous block.
bThis gene is significant, but the block in meta2.5 is smaller than that in the WTCCC2 study.
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in the final intersection network is S1PR1 (Figure 4). This is
of relevance because S1PR1 is the target of the disease-
modifying therapy Fingolimod. Again, further experi-
mental approaches are warranted for determining which
are the functionally relevant associations in each of
these loci.
We acknowledge that the lack of an independent replica-
tion is a limitation when new associations are predicted.
However, the successful identification of several bona
fide genes containing susceptibility variants, the prioritiza-
tion of different genes within a known association block,
and the proposal of candidate associations are valuable
outcomes only achieved by the integration of different
sources of evidence. Results from this approach contribute
to firmly establish that genes and pathways involved in the
immune response are the major drivers of MS risk.Supplemental Data
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